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Introduction 
 
In the last years it has become evident that allogenic blood transfusions are associated with 
increased mortality, morbidity and major adverse outcomes. Reduction in the use of blood 
products should therefore be a main focus. Furthermore the costs of red blood cell 
transfusions have been largely underestimated, even when excluding the costs for treatment of 
adverse events and prolonged intensive care and hospital stay related to red blood cell 
transfusions. Therefore Patient Blood Management was adopted by the World Health 
Organisation (WHO) in 2010 in order to improve patient outcome. The three pillars of Patient 
Blood Management comprise: 1) detection and treatment of preoperative anemia, 2) reduction 
in perioperative blood loss and 3) harnessing and optimizing the patient specific physiological 
reserve of anemia (including restrictive hemoglobin transfusion triggers). The use of point of 
care devices such as ROTEM® (ROTEM® delta, TEM® International GmbH, Munich, 
Germany) to reduce the perioperative blood loss by a goal directed correction of coagulation 
deficiencies has become a standard operating procedure in many hospitals. This approach 
allows reducing the use of fresh frozen plasma, red blood cell concentrates and platelets.  
Rotation thromboelastometry (ROTEM®), a methodology based on thromboelastography 
originally described by Hartert in 1948, is used today to rapidly assess the visco-elastic 
properties of the developing clot in surgery as well as following trauma. ROTEM® 
documents in whole blood the interaction of platelets with the coagulation factors from initial 
platelet—fibrin interaction, through platelet aggregation, clot strengthening and fibrin cross-
linking to eventual clot lysis. Compared to standard laboratory coagulation tests which are 
performed in plasma only and take at least 30-45 minutes to get results ROTEM® tracing 
provides within 10 minutes information on clotting factor activity, platelet function, any 
clinically significant fibrinolysis and allows to quickly guide goal directed transfusions of 
coagulation factors and classical blood products such as platelets. 
 
 
3 
 
Research objective 
Aim of the presented research on ROTEM® was to: 
• validate this point of care device  
• show its implication in patient blood management  
• demonstrate its usefulness in the clinical setting of trauma and cardiac surgery  
• discuss the interchangeability of standard laboratory test and ROTEM® in major 
surgery with hemorrhage  
• investigate in vitro effect of factor XIII supplementation on the clot 
 
Research summary 
Validation of ROTEM® and in vitro supplementation of factor XIII 
In a first study the validation on reproducibility (inter- and intra-assay variability) and sample 
stability over time was investigated.1 In 48 healthy patients in eight age groups (below 20 
years; 20-30 years; 30-40 years; 40-50 years; 50-60 years; 60-70 years; 70-80 years; and 
above 80 years), each containing three men and three women, pre-analytic aspects, blood was 
drawn and stored in citrated tubes at room temperature. Sample stability over time, reference 
intervals and effect of age and sex on ROTEM® parameters were assessed. The tests were 
performed every 30 min from T 0 minutes up to T 120 minutes on two identical ROTEM® 
devices with: INTEM (ellagic acid activated intrinsic pathway), EXTEM (tissue factor-
triggered extrinsic pathway) and FIBTEM (with platelet inhibitor (cytochalasin D) evaluating 
the contribution of fibrinogen to clot formation). Each test was run for 60 minutes. To 
evaluate the precision of the devices intra- and inter-assay variability was measured in citrated 
blood in ten volunteers at two points of time, using the same three tests. This study was able 
to show that blood was stable over 120 minutes thus resulting in identical results in all tests 
during the entire 2h period. In addition, the variability of the tests was minimal. The 
maximum clot firmness (MCF) measurements had a coefficient of variation of <3% for 
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EXTEM, <5% for INTEM <6% for FIBTEM. The clot formation time (CFT) showed a 
coefficient of variation of <4% for EXTEM and <3% for INTEM, for FIBTEM this value 
does not have a clinical implication. Coefficient of variation for angle alpha was <3% for 
EXTEM and <6% for INTEM and does not exist for FIBTEM measurements. The coefficient 
of variation for clotting time (CT) was <15% for both EXTEM and INTEM and does not have 
a clinical implication for FIBTEM. A small but significant difference between ROTEM® 
devices was found for the MCF in FIBTEM and INTEM as well as for the CFT and alpha 
angle in INTEM. For INTEM these differences do not have a clinical implication. For 
FIBTEM this difference in MCF results has a clinical implication and may influence the 
administration of fibrinogen thus analysis should be performed on the same ROTEM® device 
if small differences are of importance for treatment. After 10 min of running time the MCF of 
EXTEM, INTEM and FIBTEM reached at least 98% of the final MCF value, which is an 
important finding as goal directed replacement of coagulation factors can be started at that 
moment of time. Age and gender specific changes could be found showing an increase of 
MCF, angle alpha and a decrease for CFT in all tests with advancing age and a greater 
coagulability in women. 
Based on these findings a second in vitro study was performed aiming at determination of the 
impact of the addition of factor XIII on clot stability as assessed by ROTEM®.2 As factor 
XIII is an essential parameter for final clot stability and drops quickly in many clinical 
situaions to critical levels its replacement and monitoring seemed essential especially if 
results are to be obtained faster than by laboratory determination. In this trial 90 intensive care 
patients were enrolled and ROTEM® measurements were performed at baseline (no addition 
of factor XIII), after in vitro addition of factor XIII 0.32 IU, 0.63 IU, 1.25 IU and compared to 
controls where only the diluent (aqua injectabile) was added. The above factor XIII addition 
resulted in approximate factor XIII concentrations of 150, 300 and 600%. The two tests run 
were EXTEM and FIBTEM and standard ROTEM® parameters (CT; CFT; MCF, angle alpha 
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and ML) were analyzed. Additionally, laboratory values for factor XIII, fibrinogen, platelets 
and hematocrit were contemporaneously determined. Fibrinogen being an acute phase protein 
was elevated in all patients with a mean concentration of 5.2 g/l and mean factor XIII was 
lowered at 62%. This phenomenon can be considered as a relative factor XIII deficiency in 
critically ill patients and we thus introduced a fibrinogen: factor XIII ratio. With this ratio we 
were able to show that supplementation of factor XIII led to a fibrinogen concentration-
dependent increase in MCF and alpha angle and to a decreased CFT and ML in FIBTEM and 
EXTEM. These aspects showed that the addition of factor XIII increases clot firmness, 
accelerates clot formation and increases clot stability.  
 
The clinical impact of ROTEM® and its use / application in special clinical settings  
1) Jehovah’s witnesses 
As shown by the previous two studies ROTEM® is a reliable device regarding precision and 
reproducibility and can be used to guide goal directed transfusions regarding factor XIII.1,2 In 
a third study in elective cardiac surgery with a special group of patients, namely Jehovah’s 
witnesses, these findings were integrated and used in the second pillar of Patient Blood 
Management.3 Due to their refusal of blood products perioperative anemia was diagnosed and 
treated with iv iron and erythropoietin to achieve normal hemoglobin levels for the day of 
surgery. Hemodynamic optimization was attempted by fluid resuscitation, Trendelenburg 
positioning and catecholamine administration. Body temperature was continuously monitored 
and adapted to the surgical procedure to prevent additional blood loss, hypothermia ≤ 35 °C 
was avoided to reduce blood loss due to hypothermia induced coagulopathy, and warming 
systems were used. In addition to this, the Cell Saver system was applied for continuous 
autotransfusion for efficient blood salvage. The only fluid received by these patients was 
priming solution, Ringer’s Lactate and hydroxylethyl starch. Controlled hypotension was also 
used to reduce intraoperative blood loss. To minimize bleeding from the sternum bone wax 
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was used as standard in every patient. Other synthetic hemostatic agents, such as fibrin glue 
were administered to stop and minimize blood loss from diffuse bleeding. 
The intraoperative and postoperative management consisted in maintaining a good perfusion 
of organs and tissues and applying Patient Blood Management. Mean arterial pressure had to 
be between 60 and 70 mmHg, and when needed noradrenalin, phenylephrine, dobutamine and 
vasopressin were used. Laboratory controls and blood drawn was reduced to a minimum. 
Coagulation was controlled by laboratory values as well as by ROTEM® and substitution of 
fibrinogen and coagulation factors were substituted according to institutional guidelines and 
ROTEM® results.  
Male gender was predominant (64%), mean age was 63±17 years, preoperative EuroSCORE 
was 5.7±1.9, the mean preoperative ejection fraction 65±7%, mean body mass index 28±6 and 
patients presented with a classical cardiovascular risk profile. Preoperative hemoglobin, 
hematocrit and platelets were 14.5±2.0 g/dl, 42.8±4.7 %l, 255±55x103/µl. Only three patients 
required preoperative i.v. iron and erythropoietin therapy due to low hemoglobin levels (≤12 
g/dl). INR (0.97±0.07) was normal in all patients. No blood transfusions occurred, while 
hemodynamic substitution was performed with Ringers’s Lactate (873±367 ml), Voluven 
(700±388 ml) and indirect re-transfusion via the Cell Saver (474±101 ml). The mean duration 
of the procedure was 246±39 minutes, mean CPB-time 75±60 minutes, mean cross-clamp 
time 49±40 minutes and among patients who underwent the off-pump approach, no emergent 
conversion to CPB was necessary. Except for one episode of ventricular fibrillation in one 
patient which could be immediately terminated via defibrillation, no complications occurred 
postoperatively. No re-exploration for bleeding was necessary and all patients had a swift 
postoperative course. Mean postoperative ventilation time was 548±235 minutes, and except 
for two patients, all others were transferred from the ICU on the first postoperative day (mean 
length of ICU stay 25.9±12.2 hours). 
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The mean hemoglobin and hematocrit at the third postoperative day was 10.0±1.5 g/dl and 
29.5±4.5% and the mean decrease in comparison to the preoperative levels was 31±8% and 
31±7%. After a mean hospital stay of 7±1 days, the patients were discharged with mean 
hemoglobin of 10.6±1.2 g/dl and a hematocrit of 32.2±3.2%. In addition to this, it became 
apparent that the early postoperative decrease of hemoglobin and hematocrit levels was the 
lowest in patients who underwent an off-pump approach for myocardial revascularization 
when compared to all other procedures requiring CPB (25±9% vs. 33±6%; p=0.01 and 22±9% 
vs. 31±6%; p=0.04). Similarly, the decrease of platelets was significantly lower (20±12% vs. 
43±14%; p=0.01) and did not drop below the normal range of 150–400 x 103/ml even after 
off-pump surgery. The mean follow-up time was 52±34 months and was completed in all 
patients (100%, n=16). Within this period, one patient died due to a non-cardiac reason 
(pneumonia). All other patients were alive, were in good health and had returned to normal 
life. None of them reported having any major adverse cardiac events (MACE) or any 
recurrent cardiac symptoms requiring redo surgery or a re-intervention. 
These results demonstrated safety and feasibility of complex open-heart surgery in patients 
not accepting blood products and highlighted that Patient Blood Management leads to 
excellent clinical short- and long-term outcomes. Combined efforts in regard to preoperative 
hemoglobin optimization, effective intra-operative volume management as well was goal 
directed transfusions guided by ROTEM®, senior surgical staff and modern surgical 
techniques make this possible and permit complete avoidance of blood products. 
Intra- and postoperative bleeding management can easily be performed by ROTEM® and 
allows for correcting coagulation factors such as fibrinogen, factor XIII and PBSB and 
avoidance of blood transfusion. In these cases, Patient Blood Management allowed major 
cardiac surgery without using any blood. The question which has to be raised is why Patient 
Blood Management is not offered to all patients as the standard of care. 
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2) Trauma 
In a fourth study in trauma patients the question of the diagnosis of hyperfibrinolysis by 
ROTEM® was investigated as standard laboratory analysis do not provide adequate test 
within a reasonable time.4  
Hyperfibrinolysis is a pathological state that occurs when the balance between fibrinolytic 
activators and its inhibitors are disturbed and is associated with significantly higher morbidity 
and mortality. Hyperfibrinolysis is commonly found in patients suffering from liver failure 
and during the an-hepatic period of liver transplantation; during brain injury and intracranial 
surgery; postpartum hemorrhage, during the cardiopulmonary bypass period; in a disturbed 
microcirculation as well as shock conditions; and in major trauma patients. However, the 
incidence of hyperfibrinolysis is still unknown, and its occurrence has only been estimated for 
patients with liver disease and major trauma patients in the range of 30% to 46% and 15% to 
20%, respectively. One reason for the nescience regarding the incidence of hyperfibrinolysis 
may be that it is often underdiagnosed due to a lack of appropriate and real-time routine 
laboratory tests. In a two year period from April 2008 to April 2010, all emergency patients 
with hyperfibrinolysis were enrolled in this study. Hyperfibrinolysis patients were divided 
into two groups: traumatized and nontraumatized patients. The traumatized patients were 
matched with 24 polytrauma patients without hyperfibrinolysis. Data from the ROTEM® 
measurements, blood gas analysis, laboratory analysis, injury severity score, and 30-day 
mortality were collected. A total of thirty-five patients with hyperfibrinolysis could be 
identified (13 traumatized, 22 non-traumatized). Overall mortality for hyperfibrinolysis was 
54%. Mortality in traumatized patients (77%±12%) was significantly higher than in non-
traumatized (41%±10%; p=0.001, 95% CI 5%–67%) and polytrauma patients without 
hyperfibrinolysis (33%±10%; p=0.009, 95% CI 13%–74%). Hyperfibrinolysis was 
significantly (p=0.017) associated with mortality in trauma patients. In the blood gas analysis 
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representing the metabolic state, only pH (p=0.02) and potassium (p=0.01) were significantly 
lower in traumatized patients compared to the non-traumatized. 
Mortality from hyperfibrinolysis was significantly higher in traumatized compared with non-
traumatized patients furthermore hyperfibrinolysis can be used as an independent factor to 
predict mortality in trauma patients. Actually only ROTEM® provides real-time recognition 
of hyperfibrinolysis and allows early treatment. 
3) The association with standard laboratory test  
In a fifth study the important question regarding the association between standard laboratory 
tests, coagulation factor concentrations and ROTEM® in patients undergoing major surgery 
with hemorrhage was addressed.5 In 45 patient’s fibrinogen, factor VIII, factor XIII, INR, 
aPTT, thrombin time, hemoglobin, leukocytes and platelet count were simultaneously 
measured intra-operatively with ROTEM® (EXTEM, INTEM, FIBTEM, APTEM) 
measurements. ROTEM® parameters determined were: Clotting time (CT), clot formation 
time (CFT), maximum clot firmness (MCF) and α-angle. Demographic and laboratory data 
were expressed as mean ± SD and median [range]; non parametric Spearman rank correlations 
and multiple linear regressions were performed; p-values ≤ 0.003 were considered significant. 
Significant correlations (p≤0.003) were found for CFT, α-angle and MCF, in EXTEM, 
INTEM and APTEM with platelets, INR and fibrinogen. Factor VIII showed a strong 
correlation (r≥0.7 or r≤-0.7; all p≤0.003) with MCF, CFT and α-angle of EXTEM, INTEM, 
MCF of FIBTEM excluding CT of EXTEM, INTEM, FIBTEM and strong significant 
correlation for α-angle APTEM and moderate for CFT and MCF APTEM. A significant 
moderate to strong correlation of factor XIII with MCF of EXTEM, INTEM, FIBTEM and 
APTEM was found. Hemoglobin was moderately correlated (r=0.3 to 0.7 or r=-0.3 to -0.7) 
with MCF in APTEM (p=0.003). A moderate to strong correlation of the standard coagulation 
tests with all ROTEM® parameters was found, in particular the CT. The aPTT correlated 
significantly moderate to strong with CT, CFT, α-angle and MCF of INTEM. However, 
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multiple linear regressions was not able to show an influence of INR on ROTEM® 
parameters except for APTEM-MCF. A significant impact of the aPTT on INTEM-CT was 
found. EXTEM, INTEM and APTEM are significantly influenced by fibrinogen and platelets.  
These results confirm the clinical assumption that EXTEM, INTEM and APTEM are 
associated with fibrinogen and platelets levels; INTEM-CT significantly to aPTT; and 
FIBTEM significantly to fibrinogen. Factor VIII showed a significant correlation with all 
ROTEM® parameters except CT of EXTEM, INTEM, FIBTEM and CFT and MCF of 
APTEM. This means that ROTEM can be partially used instead of standard laboratory 
measurements with the advantage that results are available within a much shorter time delay. 
 
Conclusion 
The presented research elucidates the important role of ROTEM® in monitoring coagulation, 
guiding goal-directed coagulation and transfusions treatment and its use in addition or in lieu 
of standard laboratory tests.  
Furthermore ROTEM® is actually the only device able to detect hyperfibrinolysis in real time 
and therefore allowing its rapid detection and treatment. In addition, it is a predictor of 
mortality in traumatized patients. Further studies in this clinical setting are needed to evaluate 
the sensitivity of ROTEM® regarding the detection of hyperfibrinolysis, as it is possible that 
lower grades and local hyperfibrinolysis cannot be detected by the current technology. More 
studies on ROTEM® in special subgroups such as for example trauma, post-partum bleeding 
and liver transplantation are needed.  
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